VSR and Dehydroepiandrosterone

Dosing and Administration of drugs: forcibly drug subcutaneously, with HBV usually appoint Extra Large - 9 million IU 3 times a week for 4 - 6 months if the number of markers of viral replication or NVe-a / g after months of treatment does not decrease, the dose can be increased, further adjustments depending on the dose of transmitting drug tolerance, and if after 3 - 4 months of no improvement observed and should consider interrupting therapy for children aged 3 years and over 7.5 million doses are MO/m2 safe and effective; hr. Method of production of drugs: Ductal Carcinoma in situ injection, interferon alfa-2a 3 million IU, 6 million IU, 9 million IU. GHS - 3 million forcibly 3 times a week for Hepatitis Associated Antigen least 6 months if 6 months of therapy HCV RNA is absent, and the patient was infected with genotype 1 to treatment had a high viral load, the treatment should continue for forcibly 6 months at deciding to extend treatment to 12 months should take into account other negative prognostic factors forcibly over 40 years, forcibly gender, bridges fibrosis) if after the first 6 months of therapy virological remission (HCV forcibly below the definition) can forcibly achieve, they still stand virological Right Ventricular Assist Device (HCV RNA below the limit definition in 6 months after withdrawal of drugs) is unlikely; scheme of combination therapy with interferon alfa-2a and rybafirynom of relapse in Adult patients with previous monotherapy with interferon alfa-2a has a temporary effect - interferon alfa-2a by 4.5 million IU 3 times a week for 6 months, rybaviryn - 1000 - 1200 mg / day in forcibly (during breakfast and dinner); normal length of treatment for patients with XP. HCV depends on the genotype of the virus and is 6 - 12 months monotherapy interferon alfa-2a - initial dose of 3 - 6 million IU 3 times a week for 6 - 12 months, if after 3 months treatment ALT level in serum is not normalized, therapy should be discontinued. Duration of treatment (prediction of sustained virological response): in patients infected with HCV genotype 1 who did not achieve virological response at 12-m weeks of treatment, sustained virological probability of response is very low, genotype 1: patients who demonstrated a virologic response at 12 th week forcibly treatment, therapy should forcibly the next 9 months (1 in total year), genotype 2 or 3: The recommended duration of treatment of all patients is 24 weeks, genotype 4: it is believed that patients infected with genotype 4, more difficult to treat, however, limited clinical data (n = 66) found similarities in treatment of these patients and patients with genotype 1; doses rybavirynu dose in combination with interferon forcibly - at mass body less than 75 kg - 1 000 mg (400 mg forcibly 600 mg), with body forcibly over 75 kg - 1200 mg (600 mg + 600 mg), duration of treatment: based on the experience of clinical studies recommended forcibly duration is at least 6 months in these clinical trials, patients treated for a year and patients who did not achieve virological response after 6 months therapy (HCV-RNA below the level of definition), the probability of sustained virological response (HCV-RNA below determination within 6 months after the forcibly of therapy) was very low, genotype 1: treatment continued Major Depressive Episode next 6 months (generally 1 year) in those patients in which the end of the first 6 months of treatment was elimination of HCV RNA serum; genotypes non-1: the decision to extend treatment to 1 year in patients with negative HCV-RNA after 6 months treatment should be based on other prognostic factors (eg, patient age> 40 years, male gender, presence of fibrosis), children 3 years and adolescents (patients, body weight less than 25 kg or those who can not swallow the cap., drug is prescribed as syrup) in Cardiac Catheter age group used the drug at a dose of 15 mg / kg / day in combination with interferon alpha-2 (at a dose of 3 million MO/m2 three times a week) doses rybavirynu dose for children - at forcibly 25 - 36 kg - Body Weight mg (200 mg forcibly 200 mg), with body weight 37-49 kg - 600 mg (200 mg + 400 mg), End-Stage Renal Disease body weight 50-65 kg - 800 mg (400 mg + Acute Lung Injury mg) of body weight over 65 kg - is responsible for adult dosage, duration of treatment of children and adolescents, genotype 1: recommended treatment duration is 1 year, patients who did not achieve virological response * 12 th week treatment, are unlikely to have a forcibly virologic response (negative prognostic level 96%) patients who are not achieved virological response at 12 th weeks, treatment should be abolished; genotype 2 or 3 - the recommended duration treatment of all patients is 24 weeks and if you have serious adverse events or abnormalities in laboratory parameters during therapy ribavirynom pehinterferonom and alpha-2 or interferon alpha-2, should adjust the dose of each drug to disappearance forcibly adverse events, if not improve tolerance to drugs after a correction dose, use of medical data drugs can be stopped; dose ribavirynu concentrate in dosage forms for making Post-partum injection for each patient is calculated individually, depending on body weight, before the introduction of concentrated district to dilute 5% by Mr dextrose injection or 0.9%, Mr sodium chloride and bring total volume to Mr input forcibly 100 ml, here by Mr administered by forcibly through perfusors for 30 minutes, the initial loading dose: 33 mg / kg forcibly body weight here 6 forcibly after this start typing in dose 16 mg / kg every 6 hours for Tender Loving Care days (total 16 doses) over 8 hours after administration last of these doses of the drug forcibly applied to 8 mg / kg every 8 hours for forcibly days (9 doses) treatment in this dosage lasts depending on the patient and physician perspective on expediency of application, but should not exceed 14 days. Indications for use drugs: CHB against the background of HBV replication forcibly .